Oscillating expression of a key cancer gene may impact treatment approaches for patients NFCR-supported scientist Dr. Daniel Haber and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression in metastatic breast cancer that may contribute to disease progression and resistance to...
National Foundation for Cancer Research and KEW, Inc. announce a collaboration to increase awareness of the value of genetic testing. Big Data comes to Cancer Care Choices. #Research4aCure BETHESDA, Maryland (June 8, 2016) - The National Foundation for Cancer Research (NFCR) and Kew, Inc, a private oncology...
[vc_row][vc_column width="1/2"][vc_column_text css=""]Clinical Trial and Translational Medicine. Our CEO, the son of the Founder of NFCR, likes to talk about history. Franklin C. Salisbury, Jr. notes the coincidence, perhaps, that the Salisbury name has long been associated with unheralded basic research that leads to major...
New Treatments Could Shrink Breast Cancer in Just 11 Days For patients with HER2-positive breast cancer, a new combination therapy with two drugs could shrink or even eliminate their tumors in just 11 days. About 10% of breast cancers are HER2-positive, which is a subtype of breast...
Mary-Claire King, Ph.D. of University of Washington Awarded 2016 Szent-Györgyi Prize for Progress in Cancer Research (Bethesda, MD – January 21, 2016) The National Foundation forCancer Research (NFCR) announced today that Mary-Claire King, Ph.D., University of Washington professor of medicine (medical genetics) and genome sciences has been...
Dr. Daniel Von Hoff was presented this month with the Scripps Genomic Medicine Award for his "pioneering efforts" in sequencing, or spelling out, the DNA of patients with rare cancers. Dr. Von Hoff's research and clinical work advances the art of using the fully sequenced genomes...
Search NFCR
Popular searches